SETD2 and hepatocellular carcinoma: PI-103, the most potent novel HIF-1 inhibitor among the PI3K pathway inhibitors tested in this study, is a dual PI3K and mTOR inhibitor with anti-proliferative activity in leukemia [25], hepatocellular carcinoma [26], and glioma [27] cells.